1
Gately Stephen T, Wanaski Stephen P: Il 13 receptor alpha 2 antibody and methods of use. Neopharm, Gately Stephen T, Wanaski Stephen P, HEFNER M Daniel, October 14, 2004: WO/2004/087758 (5 worldwide citation)

The invention provides an antiboy direted against an IL13 receptor alpha 2 (IL13-R&agr;2) and methods of using the antibody to detect an localize IL13-R&agr;2, to diagnostic a disease characterized by expression of IL13-R&agr;2, and to kill a cell that expresses an IL13-R&agr;2.


2
WANASKI Stephen, COLLINS Stephen, KINCAID John: Dérivés darylsulfonamide, compositions en contenant et leurs méthodes dutilisation, Arylsulfonamide derivatives, compositions, and methods of use. Neurotherapeutics Pharma, WANASKI Stephen, COLLINS Stephen, KINCAID John, POSORSKE Laurence H, February 9, 2012: WO/2012/018635 (5 worldwide citation)

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatm ...


3
Hussey James, Sherman Jeff, Wanaski Stephen, Gately Stephen: Methods for dose selection of liposomal encapsulated sn38. Neopharm, Hussey James, Sherman Jeff, Wanaski Stephen, Gately Stephen, CARANGO Paul, December 15, 2005: WO/2005/117833

The present invention is directed to methods for determining pharmaceutically effective amounts of a liposomal formulation containing SN-38 (LE-SN38) by detecting polymorphisms within a uridine diphosphate glucuronosyltransferase (UGT1A1) gene. In accordance with the inventive method, LE-SN38 is adm ...